4.6 Article

Ageing Increases Vulnerability to Aβ42 Toxicity in Drosophila

Journal

PLOS ONE
Volume 7, Issue 7, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0040569

Keywords

-

Funding

  1. Eisai London Research Laboratories (UK)
  2. Wellcome Trust
  3. Alzheimer's Research UK
  4. MRC [G0701075] Funding Source: UKRI
  5. Alzheimers Research UK [ART-PG2009-4, ART-PPG2011A-14] Funding Source: researchfish
  6. Medical Research Council [G0701075] Funding Source: researchfish

Ask authors/readers for more resources

Age is the major risk factor for many neurodegenerative diseases, including Alzheimer's Disease (AD), for reasons that are not clear. The association could indicate that the duration or degree of exposure to toxic proteins is important for pathology, or that age itself increases susceptibility to protein toxicity. Using an inducible Drosophila model of AD, we investigated these possibilities by varying the expression of an A beta 42 transgene in neurons at different adult ages and measuring the effects on A beta 42 levels and associated pathological phenotypes. Acute induction of Arctic A beta 42 in young adult flies resulted in rapid expression and clearance of mRNA and soluble Arctic A beta 42 protein, but in irreversible expression of insoluble Arctic A beta 42 peptide. Arctic A beta 42 peptide levels accumulated with longer durations of induction, and this led to a dose-dependent reduction in negative geotaxis and lifespan. For a standardised level of mRNA expression, older flies had higher levels of Arctic A beta 42 peptide and associated toxicity, and this correlated with an age-dependent reduction in proteasome activity. Equalising A beta 42 protein at different ages shortened lifespan in correlation with the duration of exposure to the peptide, suggesting that A beta 42 expression accumulates damage over time. However, the relative reduction in lifespan compared to controls was greater in flies first exposed to the peptide at older ages, suggesting that ageing itself also increases susceptibility to A beta 42 toxicity. Indeed older flies were more vulnerable to chronic A beta 42 toxicity even with a much lower lifetime exposure to the peptide. Finally, the persistence of insoluble A beta 42 in both young and old induced flies suggests that aggregated forms of the peptide cause toxicity in later life. Our results suggest that reduced protein turnover, increased duration of exposure and increased vulnerability to protein toxicity at later ages in combination could explain the late age-of-onset of neurodegenerative phenotypes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease

Joshua Stevenson-Hoare, Amanda Heslegrave, Ganna Leonenko, Dina Fathalla, Eftychia Bellou, Lauren Luckcuck, Rachel Marshall, Rebecca Sims, Bryan Paul Morgan, John Hardy, Bart de Strooper, Julie Williams, Henrik Zetterberg, Valentina Escott-Price

Summary: Plasma biomarkers for Alzheimer's disease-related pathologies have made significant progress in recent years, with well-validated blood tests available for the detection of amyloid and tau pathology, as well as neurodegeneration and astrocytic activation. This study demonstrates that a combination of five plasma biomarkers, along with genetic variants associated with these biomarkers, can be used to accurately diagnose and predict the onset of Alzheimer's disease.

BRAIN (2023)

Article Clinical Neurology

Genome-Wide Analysis of Structural Variants in Parkinson Disease

Kimberley J. Billingsley, Jinhui Ding, Pilar Alvarez Jerez, Anastasia Illarionova, Kristin Levine, Francis P. Grenn, Mary B. Makarious, Anni Moore, Daniel Vitale, Xylena Reed, Dena Hernandez, Ali Torkamani, Mina Ryten, John Hardy, Ruth W. Chia, Sonja J. Scholz, Bryan L. Traynor, Clifton J. Dalgard, Debra Ehrlich, Toshiko Tanaka, Luigi G. Ferrucci, Thomas E. Beach, Geidy P. Serrano, John J. Quinn, Vivien Bubb, Ryan L. Collins, Xuefang Zhao, Mark Walker, Emma Pierce-Hoffman, Harrison E. Brand, Michael Talkowski, Bradford Casey, Mark R. Cookson, Androo A. Markham, Mike Nalls, Medhat Mahmoud, Fritz J. Sedlazeck, Cornelis Blauwendraat, J. Raphael B. Gibbs, Andrew Singleton

Summary: By studying the genetic factors of Parkinson's disease, three structural variants associated with the risk of the disease have been discovered. This is the most comprehensive study to date of the contribution of structural variants to the genetic risk of Parkinson's disease.

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Functional genomics provide key insights to improve the diagnostic yield of hereditary ataxia

Zhongbo Chen, Arianna Tucci, Valentina Cipriani, Emil K. Gustavsson, Kristina Ibanez, Regina H. Reynolds, David Zhang, Letizia Vestito, Alejandro Cisterna Garcia, Siddharth Sethi, Jonathan W. Brenton, Sonia Garcia-Ruiz, Aine Fairbrother-Browne, Ana-Luisa Gil-Martinez, Nick Wood, John A. Hardy, Damian Smedley, Henry Houlden, Juan Botia, Mina Ryten

Summary: Using a systems biology approach, Chen et al. found that genes associated with adult- and child-onset ataxia share common characteristics, including a high density of short tandem repeats. Removing the age-of-onset partition and screening for repeat expansions could improve the diagnosis of hereditary ataxia.

BRAIN (2023)

Article Clinical Neurology

Association between the LRP1B and APOE loci and the development of Parkinson's disease dementia

Raquel Real, Alejandro Martinez-Carrasco, Regina H. Reynolds, Michael A. Lawton, Manuela M. X. Tan, Maryam Shoai, Jean-Christophe Corvol, Mina Ryten, Catherine Bresner, Leon Hubbard, Alexis Brice, Suzanne Lesage, Johann Faouzi, Alexis Elbaz, Fanny Artaud, Nigel Williams, Michele T. M. Hu, Yoav Ben-Shlomo, Donald G. Grosset, John Hardy, Huw R. Morris

Summary: Researchers performed a genome-wide survival study on almost 4000 Parkinson's disease patients and identified new genetic loci associated with faster progression to Parkinson's disease dementia, including the LRP1B receptor. Parkinson's disease is a common neurodegenerative disorder, and cognitive impairment and dementia are important features in the later stages of the disease. The genetic basis for the heterogeneity in cognitive decline among Parkinson's disease patients is not fully understood.

BRAIN (2023)

Article Biology

Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas

Nirmal Verma, Gopal Viswanathan Velmurugan, Edric Winford, Han Coburn, Deepak Kotiya, Noah Leibold, Laura Radulescu, Sanda Despa, Kuey C. Chen, Linda J. Van Eldik, Peter T. Nelson, Donna M. Wilcock, Gregory A. Jicha, Ann M. Stowe, Larry B. Goldstein, David K. Powel, Jeffrey H. Walton, Manuel F. Navedo, Matthew A. Nystoriak, Andrew J. Murray, Geert Jan Biessels, Claire Troakes, Henrik Zetterberg, John Hardy, Tammaryn Lashley, Florin Despa

Summary: Impairment of vascular pathways contributes to Alzheimer's disease. Blood amylin secreted from the pancreas perturbs cerebral A beta clearance, leading to amylin and A beta co-deposits in the brain microvasculature. Altering bloodborne amylin could potentially reduce cerebrovascular amylin deposits and A beta pathology.

COMMUNICATIONS BIOLOGY (2023)

Letter Clinical Neurology

Reply: Lecanemab: turning point, or status quo? An ethics perspective

John Hardy, Catherine Mummery

BRAIN (2023)

Editorial Material Clinical Neurology

An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?

John Hardy, Catherine Mummery

BRAIN (2023)

Article Multidisciplinary Sciences

Reduced insulin signaling in neurons induces sex-specific health benefits

Maarouf Baghdadi, Tobias Nespital, Andrea Mesaros, Sandra Buschbaum, Dominic J. Withers, Sebastian Gronke, Linda Partridge

Summary: Reduced insulin/insulin-like growth factor signaling (IIS) extends health and lifespan, but the exact tissues involved are unknown. This study found that lack of IRS1 in liver, muscle, or fat does not increase lifespan or improve health, but neuronal loss of IRS1 specifically in old males leads to improved health and metabolic adaptations consistent with activated stress response.

SCIENCE ADVANCES (2023)

Correction Neurosciences

Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases (vol 9, 70, 2023)

Regina H. Reynolds, Aaron Z. Wagen, Frida Lona-Durazo, Sonja W. Scholz, Maryam Shoai, John Hardy, Sarah A. Gagliano Taliun, Mina Ryten

NPJ PARKINSONS DISEASE (2023)

Article Neurosciences

Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases

Regina H. Reynolds, Aaron Z. Wagen, Frida Lona-Durazo, Sonja W. Scholz, Maryam Shoai, John Hardy, Sarah A. Gagliano Taliun, Mina Ryten

Summary: Genetic correlation (r(g)) can provide insights into shared biological mechanisms. Neurodegenerative and neuropsychiatric diseases have minimal global r(g), but local r(g) can exist. Applying LAVA, researchers found local r(g) between several neurodegenerative and neuropsychiatric diseases, highlighting potential common therapeutic targets.

NPJ PARKINSONS DISEASE (2023)

Article Biology

Toxicity of C9orf72-associated dipeptide repeat peptides is modified by commonly used protein tags

Javier Moron-Oset, Lilly K. S. Fischer, Mireia Carcole, Ashling Giblin, Pingze Zhang, Adrian M. Isaacs, Sebastian Groenke, Linda Partridge

Summary: Hexanucleotide repeat expansions in the C9orf72 gene are the most prevalent genetic cause of amyotrophic lateral sclerosis frontotemporal dementia. Transcripts of the expansions translated into toxic dipeptide repeat (DPR) proteins. This study investigated the effects of protein tags on DPR toxicity using Drosophila.

LIFE SCIENCE ALLIANCE (2023)

Article Clinical Neurology

The amyloid-β pathway in Alzheimer's disease: a plain language summary

Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L. Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L. Masters, Min Cho, Lars Lannfelt, Jeffrey L. Cummings, Andrea Vergallo

Summary: This summary reviews the evidence supporting the role of the amyloid-b (Ab) pathway in Alzheimer's disease (AD) and emphasizes the importance of targeting this pathway in early stages of the disease. Understanding and targeting the A beta pathway can lead to better therapeutic outcomes and management of AD.

NEURODEGENERATIVE DISEASE MANAGEMENT (2023)

Article Cell Biology

Dietary restriction mitigates the age-associated decline in mouse B cell receptor repertoire diversity

Carolina Monzo, Lisonia Gkioni, Andreas Beyer, Dario Riccardo Valenzano, Sebastian Gronke, Linda Partridge

Summary: Aging impairs immune function, but dietary restriction (DR) can attenuate this decline. In this study, it was shown that DR preserves B cell receptor (BCR) repertoire diversity and reduces clonal expansions during aging in mice. Remarkably, mice starting DR in mid-life have similar BCR diversity and clonal expansion rates as mice on chronic DR. These findings suggest a potential role of B cell repertoire dynamics in age-related health.

CELL REPORTS (2023)

Article Medicine, Research & Experimental

Deep learning-based polygenic risk analysis for Alzheimer's disease prediction

Xiaopu Zhou, Yu Chen, Fanny C. F. Ip, Yuanbing Jiang, Han Cao, Ge Lv, Huan Zhong, Jiahang Chen, Tao Ye, Yuewen Chen, Yulin Zhang, Shuangshuang Ma, Ronnie M. N. Lo, Estella P. S. Tong, Vincent C. T. Mok, Timothy C. Y. Kwok, Qihao Guo, Kin Y. Mok, Maryam Shoai, John Hardy, Lei Chen, Amy K. Y. Fu, Nancy Y. Ip

Summary: Zhou et al. utilize deep learning to improve polygenic risk analysis for Alzheimer's disease. Their computational approach outperforms existing statistical methods and helps to identify potential biological mechanisms of Alzheimer's disease risk.

COMMUNICATIONS MEDICINE (2023)

Article Cell Biology

Genome-wide structural variant analysis identifies risk loci for non-Alzheimer's dementias

Karri Kaivola, Ruth Chia, Jinhui Ding, Memoona Rasheed, Masashi Fujita, Vilas Menon, Ronald L. Walton, Ryan L. Collins, Kimberley Billingsley, Harrison Brand, Michael Talkowski, Xuefang Zhao, Ramita Dewan, Ali Stark, Anindita Ray, Sultana Solaiman, Pilar Alvarez Jerez, Laksh Malik, Ted M. Dawson, Liana S. Rosenthal, Marilyn S. Albert, Olga Pletnikova, Juan C. Troncoso, Mario Maselis, Julia Keith, Eric Int LBD Genomics Consortium, Ali Int ALS FTD Consortium, Pentti PROSPECT Consortium, Toshiko Tanaka, Eric Topol, Ali Torkamani, Pentti Tienari, Tatiana M. Foroud, Bernardino Ghetti, John E. Landers, Mina Rtyen, Huw R. Morris, John A. Hardy, Letizia Mazzini, Sandra D'Alfonso, Cristina Moglia, Andrea Calvo, Geidy E. Serrano, Thomas G. Beach, Tanis Ferman, Neill R. Graff-Radford, Bradley F. Boeve, Zbigniew K. Wszolek, Dennis W. Dickson, Adriano Chio, David A. Bennett, Philip L. De Jager, Owen A. Ross, Clifton L. Dalgard, J. Raphael Gibbs, Bryan J. Traynor, Sonja W. Scholz

Summary: This study characterized the role of structural variants in Lewy body dementia (LBD) and frontotemporal dementia (FTD)/amyotrophic lateral sclerosis (ALS). The researchers discovered a novel risk locus for LBD and found associations between known structural variants and FTD/ALS. Rare pathogenic structural variants were also identified in both LBD and FTD/ALS. The study provides a catalog of structural variants for further understanding of the pathogenesis of these forms of dementia.

CELL GENOMICS (2023)

No Data Available